MIR17HG targets TGF-β receptor type 2 (TGFBR2) (Ma et al., 2016) (Mirzamohammadi et al., 2018), and cases deficient for MIR17HG are associated with excessive TGF-β signaling, which is supported by the fact that treatment with a TGF-β receptor inhibitor, LY364947, prevented the skeletal defect and microcephaly in the Feingold syndrome type 2 mouse model. This evidence concerns the gene MIR17HG and Feingold syndrome type 2.